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INTRODUCE ION

Cystic Fibrosis (CF), with an incidence of approximately 1
l
2 •
in 2000" and a gene carrier rate of between 3 and 5 percent,
is
the most frequently occurring lethal hereditary disease of
Caucasians in this country*

Rare among non-Whites* the CF gene

is five times more common in the general U„S„ population than
the gene for the next most frequent lethal hereditary disease,
sickle cell anemia*
While a definitive method for diagnosis of the disease, the
sweat test, has been available since 1953,^ there has existed no
such method for reliably identifying those heterozygous for the
CF Gene.

In March, 1975, Chandra et al,,

g

described a study m

which, by radioimmunoassay, they were able to detect differences in
the levels of serum Alpha^-Fetoprotein (AFP) between normals, those
heterozygous for the CF Gene, and those homozygous for the same
Gene.

This, if reliably reproducible, would present a means for

early identification of those at risk for producing a child with
CF, and would provide the opportunity for adequate genetic
counselling.

Because of this, our interest in this means of

heterozygote identification was greatly aroused and so we
attempted in this study to determine if the population of hetero¬
zygotes having contact with Yale-New Haven Hospital (YNHH) could be
similarly identified

REVIEW OF THE LITERATURE

Cystic Fibrosis

Cystic Fibrosis is a truly protean disease® classically
presenting with the triad of chronic pulmonary diseases pancreatic insufficiency and abnormally elevated sweat electrolytess
but frequently manifested as well by such entities as hepatic
cirrhosis, rectal prolapse,
polyps.

intestinal obstruction, and nasal

Meconium ileus, virtually pathognomic of CF, is present at

birth in 10-15% of children with the disease^ and is often
complicated by meconium peritonitis, volvulus, and/or atresia.
Patients beyond the newborn period may present with the
syndrome of meconium ileus equivalent marked by intestinal
obstruction due to tenacious impacted stools.
If untreated, children with CF typically exhibit failure to
thrive despite ravenous appetites, foul-smelling stools, and
abdominal distension.

Steatorrhea, due to the malabsorption

caused by pancreatic insufficiency, can be quite severe, with

2

fecal fat content averaging 4-5 times normal.^

The children tend

to be small, with below average body weights, and appear malnourished.
Liposoluble vitamin deficiencies (especially Vitamins A and K) may
occur.

Early diagnosis and symptomatic therapy may promote normal

growth rates and physical appearance.

Despite the fact that symptoms

may regress during the period of adolescence* puberty may be
delayed.^
Because of the elevated levels of electrolytes found in the
sweat of CF patients, hot weather presents the considerable threat
of severe sodium depletion and vascular collapse.

Chronic

pulmonary disease is a prominent feature of CF, eventually develops
in all patients, and is generally severe and progressive.
of onset varies,

Time

but initial features usually include wheezing

and dry, nonproductive couqh.

Atalectasis is not uncommon, and

in some instances may present as the first manifestation of the
O

disease.

Mucoid impaction of the bronchi presents as one of the

most common complications.

Episodes of pneumonia are frequent in

some patients with Staph loco ecus aureus and Pseudomo nas aeruginosa
(probably secondary to antibiotic therapy) being the most common

9
infecting organisms.'

As pulmonary involvement becomes chronic

and symptoms progress, chronic productive cough, wheezing and
tachypnea, and cor pulmonale may become severe.

Pulmonary

function tests show decreased vital capacity and an increase in
airway resistance proportional to the severity of the obstructive
disease.

Barrel-chest deformity and digital clubbing are common.

The most common cause of death is acute respiratory distress
#
r\
resulting from pneumonia and anoxia.
CF occurs in approximately

2%

of cases.

The liver involvement in
These patients, most

commonly in their teens, develop clinical liver cirrhosis (pathologi¬
cally focal bilary cirrhosis).'1'0

Increased consistency of the organ

-4

and a nodular surface are noted.

Elevations of serum ceruloplasmin*

low serum cholinesterase* elevated alkaline phosphatase, and

8
abnormal BSP retention are confirmatory tests of this complication.
Patients dying early in life commonly show small scattered areas
of hepatic abnormality at autopsy.

Plugs of inspissated material

are seen in some of the small bile ducts, suggestive of stagnation
of secretions.

Early fibrosis around the distended ducts and

biliary ductule multiplication in the portal tract may be present.^
Patients with cirrhosis may develop portal hypertension, hyper™
splenism, and bleeding esophageal varices.
While the clinical manifestations of CF may vary, it seems
clear that the disease is transmitted as an autosomal recessive
trait.In addition, Danks et al.-^ suggests that it is quite
likely that the disease may be caused by a single mutant allele at
the locus concerned.

There currently exists no adequate explanation

for the high carrier frequency for CF observed in the Caucasian
population.

A high mutation rate, unlike that observed for other

recessive traits, would be required in order to maintain the
observed incidence by mutation alone.

2

In attempting to explain

I O

this, Anderson et al«

have postulated a heterozygote advantage

of increased fertility of female CF carriers.
advantage is quite possible, McCombs

While such an

describes it to have been

calculated to be about 2% and therefore difficult to detect.
Several theories exist as to the pathogenesis of CF, each
attempting to explain the myriad of symptoms characteristic of

5
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the disease in terms of a single basic defect.

These theories have

been well described by numerous authors.lslls^^

Among the

most popularly accepted are four which attribute the basic
pathogenesis of CF to ion transport dysfunction, abnormal secretions,
autonomic dysfunction, and abnormal serum factors respectively.
The abnormally elevated level of sodium and chloride (and to
some extent potassium)

in the sweat of CF patients stands as the

most constant feature of the disease,-'0 and. as such lends great
reliability to the sweat test used for its diagnosis.

The reason

for these observed elevations, however, remains obscure.

CF is

marked by no morphologic differences in sweat glands,rates of

]8

sweating, '
of sweat.

19
'

or in the concentration of the organic constituents
Schulz,

20

however, demonstrated by micropuncture

techniques a failure in the reabserption of sodium from the fluid
pi

secreted into the sweat gland duct.

Mangos,

on the basis of

microperfusion studies, concluded that this failure in reabsorption
was due to an inhibitory effect exerted intraluminally by the sweat
of affected persons.

In 1967, Mangos and McSherry

22

isolated a

nondialyzable heat labile factor from CF sweat and saliva which
inhibited sodium reabsorption in the parotid gland of rats and
in the normal sweat gland.The sweat glands in CF appear to be
less sensitive than normal to the effects of salt-retaining steroids.15
Balfe et al.24 examined active transport of sodium in the
erythrocytes of CF patients.

They reported both sodium pumps I and

II to be decreased in activity in the red cells of children with CF.

6
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While pump I appeared normal in parents of CF patients* th

as

a notable decrease in pump II (ethacrynic acid-sensitive)

ivity

in their red cells as compared with those of normal controls.

Other

investigators have* however* been unable to support these observations
Gibson et al.^ have attempted to explain the basic defect
of CF in terms of the abnormally high calcium content observed in
all glycoprotein-rich secretions in CF (e.g.fl those elaborated by
exocrine glands).

Calcium levels in these secretions are elevated

despite the presence of normal serum calcium* phosphorous*and
probably sweat calcium levels.'"'7

Gibson et al.26 report the

presence of a factor in CF serum which produces calcium hyper¬
secretion* while Horton et al.,28 based on their findings of
reduced calcium-dependent red cell ATP-ase in CF erythrocyte ghosts*
propose a defective resorptive mechanism as the reason for calcium
elevations.

Hadden et al.,25 however* failed to demonstrate a

defect in CF patients of the calcium active transport system* which
requires calcium-dependent ATP-ase.

Another source-*-^ attributed the

high concentrations of calcium in exocrine secretions to the
inclusion of excessive amounts of calcium in secretory granules.
Gibson^0 suggests that excess calcium secretion by exocrine glands
results in the hyperpermeability of mucus which is therefore unable
to inhibit the passive flow of water and small ions.

This would

result in the elaboration of abnormally highly concentrated and
hyperviscous secretions which Johansen et al.^ claim might result
in direct tissue damage and duct obstruction, eventually leading to

25
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the glandular lesions (lungs, pancreas* livers
characteristic of CF.

intestine)

Di Sant'Agnese1 has alternatively suggested

that this hyperviscosity might be due to the formation of a calciumglycoprotein complex.

Glycoprotein quantities in CF secretory glands

are said to be normal, but they have been shown to have an
29 90
abnormal composition with an increased fucose to sialic acid ratio.^5"
Saliva elaborated by the submaxillary gland in CF is rich in
glycoproteins and abnormal in its make-up and appearance.

31 29
*

CF saliva contains elevated amounts of calcium, fucose, sialic
acid, hexose, and total protein. ^

It is turbid in appearance, but

can be cleared to resemble normal saliva by the addition of
chealating agents.

The addition of calcium to normal saliva results

in increased turbidity.^2

as j[n sweat,

sodium and chloride concentra¬

tions have been noted to be elevated in CF saliva,^3
In 1959, Roberts^ postulated that the basic defect in CF
might be due to a chronic excess ox parasympathetic stimulation of
the body’s cholinergic glands,

including Brunner’s glands, sweat

glands, pancreatic, bronchial, and salivary glands.

The histologic

changes seen in the disease were, he proposed, due to the exhaustion
of these glands.

This hypothesis has long been a popular one since

the autonomic nervous system innervates and controls the secretory
function of the very same exocrine glands which are most notably
affected in CF.

Chernick et al.31 demonstrated that parasympathomimetic

stimulation in normal children (but not in adults) resulted in the
production by them of saliva similar in composition and appearance to

8

-

that of CF patients.

-

They also showed that CF saliva became

clear and normal in the concentrations of its constituents (except
for calcium which remained elevated) after injection with the
adrenergic blocking agent* guanethidine,00

An examination of the

adrenal medullas of CF patients at autopsy has revealed the presence
of elevated levels of catecholamines.''0

The observation of

elevated urinary Catecholamine metabolites in CF was made in
1967 (as recorded by di Sant{Agnese^) * but others found these
0*7

levels to be normal.

OQ

Rubin et al.

concluded that a generalized

autonomic dysfunction existed in CF on the basis of differences
they observed between the pupillary reactivity of individuals with
CF and normals under conditions of rest and stress* and after
termination of painful stimuli.

They concluded that the CF patient

suffered from adrenergic underactivity.

Spock,^ however,

suggests

that rather than being a generalized autonomic disturbance, the
site of such a defect in CF would more likely be at the
neuroeffector junction or within the affected secretory gland
•

itself.

•

•

Working on isolated dog salivary glands, Dische et al.

QO

reported an alteration in glycoprotein composition reminiscent
of that seen in CF (increase in fucose and decrease in sialic
acid) after pilocarpine stimulation.

On the other hand, chronic

pilocarpine^50 or atropine^ stimulation has failed to reproduce the
CF complex in experimental animals.

An attempt to alleviate or

reverse symptoms in CF patients by sympathetic blockade with
cocaine, followed by a right-s.ided complete splanchnicectomy

9
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has proved ineffective.42
Spock et al.

43

demonstrated in 1967 the presence of a heat

labile, nondialyzable factor in the sera of children with CF which
disorganized the regular ciliary rhythm in rabbit tracheal explants.
This ciliary dyskinesia factor (CDF), was detected in the sera of
obligate heterozygotes for the CF Gene, though in lower concentrat.ion*
While initially encouraging as a possible means for heterozygote
detection, this technique is based on a subjective judgment and has
proved unreliable, as normal sera have been observed to produce the
CDF effect.44
of

In 1969, Bowman et al.4^ introduced a modification

Spock*s technique which employed oyster gill cilia in place of

rabbit tracheal explants, and which was more quantitative in that
the time required for cessation of all ciliary motion was the
recorded value for each serum tested.
in the same settings as did Spock.

The group found CDF effects

The bulk of the work which

has been done on CDF has employed the oyster gill technique since the
time of its introduction.

Much work has been done in attempting to

determine the exact identity of CDF.

In 1970, Bowman et al.

46

determined that CDF migrates in they-globulin fraction of serum,
raising the possibility that it might be a specific antibody.
Herzberg et al.,4^ however, determined that while associated with
the IgG fraction, CDF does not interact with oyster cilia in a
typical antigen-antibody reaction.

Danes et al.

have provided

evidence to show that CDF is probably simply bound to certain
Y-globulins.

It was shown in 1972

49

that the CDF effect could be

10
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produced by the medium from in vitro cultures of skin fibroblasts
from those with CFS but not by fibroblast from normal individuals®
Conover et al.50 have presented evidence that anaphylotoxin (C3a)
is a pre-CDF which, both at the cell surface and bound to IgG
(C3a~IgG complex is CDF),

is the prime mediator of the various

pathophysiologic conditions seen in CF.

They suggest that C-3a may

act at the secretory cell surface to facilitate extrusion of granules
or other materials reflecting the cell’s function (e«g», digestive
enzymes from salivary cells).

This secretion, rapidly terminated in

the normal state by a degradative enzyme (anaphylotoxin inhibitor),
would continue if such enzyme were deficient or absent, resulting
in the accumulation or secretory products leading to the classic
picture of organ involvement seen in CF»

Thus, they suggest

a

defect in or deficiency of anaphylotoxin inhibitor would be the
primary defect in cystic fibrosis.

Polley and Bearn^l in 1971

also suggested the possible relation of CDF to the complement
system.

While this appears as one of the more promising

developments in the research on CDF, factors such as the lack of
clear definition of CDF as central to the pathogenesis of CF, or
byproduct of the disease; the report by Wood and di Sant’ Agnese'"'
suggesting that CDF activity may be present in normal serum even
with the oyster assay; and the alternate claim of identification of
CDF as amylase by Doggett et al.,

*

must be resolved.

Another long recognized defect in CF is the observation made
by Mangos and McSherry^2 that sweat and saliva from affected

11
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individuals markedly inhibit the reabsorption of sodium when
infused into rat parotid ducts.

Whether the factor responsible

for this effect and CDF are the same is not known.

Murakami and

Eckert^b have shown that the regulars well coordinated beating of
cilia is dependent on normal calcium transport across cell membranes
It is indeed possible that the CDF may produce its effect by causing
abnormal calcium flux or abnormal calcium secretion by exocrine
glands as Gibson postulated.^

Spock et al.^ speculated that the

serum factor he described might alter the transport of electrolytes*
thereby producing changes in the action potential within the cell
and resulting in the observed ciliary dyskinesia.
McSherry,

op

Mangos and

observing that positively charged molecules acted in

the same way as their CF factor to inhibit sodium transport in the
parotids of rats,

suggested that this factor might be such a

positively charged molecule, whose effect was the result of an
alteration in membrane permeability.

Interested in this possibility

they added heparin, a negatively charged molecule which has been
shown to form complexes with positively charged molecules, to the
sera of individuals with CF.

Upon doing so they noted an apparent

negation of the inhibitory effects originally exhibited by these
sera.
et al.

CDF has been shown to bear a positive charge.^ and Bowman
observed that positively charged molecules, other than

CDF, could produce the same effect on oyster cilia.
Doggett et al.'JO»^M,'J

Finally,

demonstrated that heparin could reverse the

dyskinetic effects of CF serum and saliva upon oyster cilia, both

12
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in vivo and in vitro.
Danes and Bearn^0 have demonstrated that fibroblasts of CF
patients contain an abnormal cytoplasmic substance which causes them
to stain metachrornatically.

They also noted that the fibroblasts

of heterozygous relatives showed the same metachromasia which was
absent from the stained fibroblasts of normal subjects.

Two

different patterns of metachromatic staining were identified.

These

are genetically consistent (CF patients and parents always show the
same type) and may therefore be demonstrating heterogeneity of
the CF locus.

The observed staining is thought to represent

accumulated acid mucopolysaccharides whose presence, Spock^ has
speculated, may be due to a cell membrane defect, a defect in th
lysozymes or a specific enzyme within the lysozyme which normal],
breaks down mucopolysaccharides, or an increased synthesis due to
lack of an inhibitor.

The exact significance of the observed

staining characteristics of CF fibroblasts remains uncertain.
With regard to heterozygote detection, the only test available
in the recent past upon which to base genetic counseling of those
at risk has been the oyster gill bioassay for CDF.
however, by the condemnation of those rejecting it,

This test,
and the

admission of some ox those employing itf^ is unreliable and
subject to inherent variability due to the fact that it is a
bioassay.

It can also be expensive and difficult to set up--all in

all unsuitable for mass screening for detection of heterozygotes.
In attempting to isolate and identify CDF by an alternate means.
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Atland et al.59 employed isoelectric focusing and disc electro¬
phoresis.

They were successful in isolating a factor from the serum

of CF patients and obligate heterozygotes which they felt to be
similar to,

if not identical with, CDF.

Wilson and Fudenberg^

also employed isoelectric focusing to obtain similar results in
successfully identifying CF homozygotes and heterozygotes.
Swachman et al.^ were able to distinguish all homozygotes and

90% of the heterozygotes in their study from normal subjects.
They did this by utilizing the Ussing chamber technique to
measure differences in the electrical properties (potential
difference and resistance) of rat jejunum in the presence of the
sera to be tested.

Finally, as mentioned in the introduction,

Chandra et al.^ have described the ability to distinguish CF patients
and obligate heterozygotes from normal subjects on the basis of
their serum Alpha^-fetoprotein levels.

This work, forming the basis

for the current study, will be more fully discussed in the next
section of this paper ("Alpha^Fetoprotein").
What occurs, then, from a review of the evidence for each of
the four major theories of CF pathogenesis is a multiplicity of
results,

some positive, some negative, from which no clear cut

conclusions can as yet be drawn.

The pleiotropic effects of the CF

Gene will continue to mask the identity of the basic defect in this
very common disease until we are able to develop a better working
knowledge of the basic principles behind the pathologic features of
each of the systems involved.

Only then can we hope to recognize the
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set of generalised principles at work in all of these systems which
produces the entity we call cystic fibrosis.

Alpha^-Fetoprotein (AFP)

In the progression from fetus to adult, there is presumably a
complex sequence of biochemical "on-off" switches which controls
the normal pattern of growth.

It is possible that the relatively

uninhibited growth of malignant cells is somehow representative of
a de-differentiation process causing the cells to revert to embryonic
growth patterns.

The first immunological evidence that embryonic

phase-specific antigens (PSA) might be related to tumor antigens
appeared in 1932 and,
60,66,67,62,63,64

since that time, numerous investigators

^ave examinec] this possibility.

Among the more

intriguing and useful applications of this concept has been the
measurement of elevated levels of embryonic PSA in adults, and the
use of such measurement both to. indicate the presence of neoplastic
disease and to monitor its course and response to treatment.

In

recent years, the presence of elevated levels of a protein which
normally occurs in the sera of human fetuses (variously known as
fetoprotein, postalbumin, <=<^"fetoprotein, and ^-globulin) has been
demonstrated in a large number of patients with primary tumors of
the liver or with teratoblastomas.

Its reappearance in large

quantity in the serum of adults has resulted in the generali2ed
acceptance of AFP measurement as a diagnostic test for the presence

15
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r ,,
•,
67,68
of these neoplasms.
*
AFP was first identified by Pedersen in 1944^ in sera from
the newborn calf and was named "fetuin" at that time.

After

detecting a trace of AFP in human cord blood, Bergstrand and
Czar

70

extended this observation and later reported the detection

of AFP in the serum of human fetuses less than 5 months old.

71

9

79

The new protein was found to migrate between albumin and ^-globulin
on paper electrophoresis.
molecular weight between

It was further established to have a
64000^

and 70000^*^ and to be formed

by a single polypeptide chain.7Ss74

Reliable detection and measurement

initially presented formidable technical problems, ° but with the
development of more sophisticated immunological techniques 72s^7
these problems were overcome,
inquiries.

setting the scene for more detailed

A summary of immunological techniques for AFP detection,

along with their sensitivities and applications is provided in
Table I from Adinolfi et al."^°

TABLE I
SOME IMMUNOLOGICAL METHODS TOR THE
DETECTION AND ESTIMATION OF AFP*

Methods
Double diffusion in
agar gel
Counter-current
electrophoresis
Single radial diffusion
Electroimmunod illusion
(rocket)
Radioimmunoassay
Enzyme-lmked
immunoassay
Reverse agglutination

|

Scnsitivityf

1

2-5 r^g/ml

i

0.25-0.5 ug/ml

1

|
1
{

2.5 Mc/ml
0.5-1.0 nc ml
(50 r.g ml4
2-5 nq ml
5 ng,mi
5 ng/ml

Application
Detection
Detection;
semi-quantitative
Quantitative
Quantitative
Quantitative
i Quantitative
j
Quantitative

• For references see text.
■f Lowest sensitivity using conventional technique.
t The sensitivity is increased using an immunoradioassay or an immunoperoxidase lest.

(Adinolfi, A., et al., Alpha-feto-protein during development
and in disease.
J. Med. Gen., 12:138-151, 1975.)
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Recent results with radioimmunoassays for AFP have demonstrated
even greater sensitivities than those quoted by Adinolfi* with
Ruoslahti and Seppala74 reporting a sensitivity threshold of
250 picograms per milliliter.

Other workers

have reported

sensitivities down to 165 ng/ml for the single radial diffusion
technique.

Sizaret^8 has utilized the technique of radioelectro-

complexing (a radioimmunoassay which employs electric current first
to bring together the immunoreagentss and then to separate the
bound from the unbound radiolabelled antigen) to reach sensitivities
between 200 and 400 picograms per milliliter of AFP.
By means of the immunodiffusion techniques* it has been
established that AFP is normally present in human fetal serum*
making its appearance in measurable quantities by the 4th week of
development.

The levels of the protein rise steadily over the next

1- 3 months* reaching their peak values of 200-400 milligrams per
100 milliliters by 12 to 16 weeks of gestation.'/7j ^

At this time

AFP may comprise one-tenth of the total fetal proteins.74

Beyond this

period* AFP levels fall rapidly* until at birth concentrations of
2- 17 milligrams per 100 milliliters77*^ or less88 are present.

In

the period immediately after birth, this level decreases (T’P = 3-5 days8^)
to levels detectable only by radioimmunoassay.

Any form of acute

liver disease during this period of neonatal decrease can result
m transient elevations of serum AFP.

Increased levels of serum

AFP (44-2800 micrograms/milliliter) were found in children with
ataxia-telangiectasia, but were not detected in those with various

37
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other immune deficiency diseases.

The persistence of high AFP

levels in these patients is associated with the hypothesis that
the primary defect is an abnormality

of tissue differentiation.

The generally accepted range of AFP levels measurable in normal
subjects by radioimmunoassay is 1-25 ng/mls

although levels

as high as 50 ng/ml have been reported in apparently normal
subjects free from detectable disease.
Noting the decrease in fetal serum AFP levels during the last
trimester, Bergstrand et al.^2 have attempted to correlate AFP
levels with fetal maturity.
in premature infants'
full"term infants.

Their results indicated that AFP levels

sera were generally higher than those in

They also found AFP levels to be more closely

correlated with gestational age than either birth weight* total
serum protein level* or serum albumin,
SeppSlS and Ruoslahti-1

also found a correlation between

amniotic fluid AFP levels and gestational age* with AFP levels
decreasing with advancing gestation during the last trimester.
By employing radioimmunoassay* these experimenters were able to
detect AFP in amniotic fluid of normal fetuses from all three
trimesters.

Prior to this*

immunodiffusion techniques had only

been able to detect amniotic AFP during the first 22 weeks of
gestation.

^

Amniotic AFP levels decreased from levels of 2600-

2800 nanograms per milliliter during the second trimester* to
levels of 15-535 nanograms per milliliter during the third
trimester.

AFP is known to be produced by the fetal liver and
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yolk sac.^

Sepp^lS and Ruoslahti83 have suggested that the high

amniotic component of AFP seen early in gestation may be derived
from urinary AFP.

This suggestion was made on the basis of

their measurements of early fetal urinary and amniotic AFP as well as
their observations of elevated amniotic AFP in the case of fetuses
with congenital nephrosis.
Abnormally elevated amniotic AFP levels have been used at,
various times of gestation as a marker for an affected fetuso

Thuss

between 18 and 36 weeks of gestation, elevated amniotic AFP levels
have been correlated with and successfully diagnosed anencephaly
and spina bifida in utero.Seller and Adinolfi^ have suggested
that the high levels of amniotic AFP in the case of open neural-tube
defects is due to the transfer of AFP from the CSF.

They detected

AFP levels of 52 to 1220 micrograms per milliliter in the CSF of
normal fetuses from 16 to 25 weeks of gestation.

In a prospective

OCA

study, Harris et al.

concluded that most cases of spina bifida

and anencephaly were detectable by a combination of amniotic AFP
measurement and ultrasound before 20 weeks of gestation, providing
the opportunity for selective abortion.

They found closed neural-tube

defects to be associated with normal amniotic AFP levels while open
neural-tube defects showed low AFP levels if measured during the
last trimester when only a small amount of the protein is synthesized
by the fetus.

87
SeppaiM

noted elevated AFP levels in both amniotic fluid

and in maternal serum in the case of intrauterine death.

Adinoifi
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et al.
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have suggested that these elevations may be due to

transendation of AFP in the amniotic fluid and transfer of the protein
across the placenta associated with fetal death.

This mechanism

may also explain elevated maternal serum AFP levels which have
been noted in the event of severe distress.^

Elevated amniotic

AFP levels in cases of severe Rh incompatability have been attributed
to increased synthesis of AFP.°ys^°
Hirose*^ has well summarized the implication of abnormally high
AFP levels in pregnancy.
(1) fetal malformation:
when maternal serum-AFP
level is within the normal range but the amniotic
fluid AFP concentration is markedly elevated; (2)
placental dysfunction:
when the maternal AFP
level is markedly elevated irrespective of the level
of AFP in amniotic fluid; and (3) placental
dysfunction combined with fetal malformation:
when
both maternal serum-and amniotic-AFP levels are
extraordinarily elevated.
QO

SeppSlS and Ruoslahti

have reported* by measurement with

radioimmunoassay* high levels of AFP in maternal sera throughout
pregnancy.

They found levels of 18-119 nanograrns per milliliter

during the first trimester* 96-302 nanograms per milliliter during
the second trimester, and 160-550 nanograms per milliliter during
the third trimester.

At labor these levels were between 103 and

400 nanograms per milliliter.

The facts that the maternal and

fetal serum AFP levels were significantly correlated (the highest
maternal AFP levels were measured in those whose fetuses had highest
levels, though maternal peak levels lagged behind fetal peak levels)
and that maternal AFP levels fell rapidly during the post partum
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period (TS’ = 5 days as in infant) suggested to these investigators
that the fetus is the source of maternal AFP elevation,

Ihe

alternative possibility that the hormonal changes of pregnancy
might temporarily de-repress AFP synthesis was considered by
no

SeppSlcl.' '

This investigator found no rise in AFP following the

hormonal changes induced by oral contraceptives,

SeppSlS and

Ruoslahti^ were unable to demonstrate the presence of maternal
antibodies to AFP,

The mean levels of maternal serum AFP have been

93
found to be higher for multiple pregnancies than for single ones/
The exact biological function of AFP in humans remains unknown,
OA

Uriel et al,y

found that the hormones estrones estradiols estriol*

and diethylstilbestrol are bound by AFP in the rats and suggest
that AFP may play a role in hormonal transport and in the fetomaternal relationship across the placental barrier in this animal.
The fact that estrogen binding in humans is known to be associated
with albumin and a P-globulin and the fact that Swarty et al.^°
were unable to demonstrate estrogen-binding by human AFP suggest
that AFP probably plays a different role in man.
on the part of Murgita and Tomasi

Observations

on the effects of AFP on

1° and 2° antibody responses in mice has led them to suggest a
possible immunoregulatory function for AFP,

They postulate

that AFP may in normal development protect the fetal mouse against
immunologic attack by the mother.

Again these results are not

necessarily applicable to humans,
Abelev et al.

first reported that transplantable mouse
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hepatomas synthesized and secreted into the blood anet-globulin
immune logically identical to AFP* in 1963.

In 196d* Tatarinov

extended this observation to human patients with hepatocellular
carcinomaSince that time* numerous studies examining the
relationship between AFP., hepatoma, and liver disease in general
,
, 80,98.99*100
have appeared.
3
3
s
Employing double-gel diffusion, AFP is detectable in the sera
of some 30% of Caucasian hepatoma patients in the U.S.^

This

figure is increased to between 50%^® and 60%-^- of Caucasian
hepatoma patients aid a higher percentage of other racial groups
if the more sensitive counterelectrophoresis and electroimmunodiffusion
techniques are employed.

Between 75% and 90% of hepatoma patients

in Africa have been found to be AFP-positive by these techniques.

1 f)9

1 03
In addition to geographic variations* Bagshawe and Parker'
have
observed variation in the detectability of AFP in the sera of
hepatoma patients of the same ethnic background who differed in age.
Elevated AFP levels were detected significantly more frequently
in hepatoma patients less than 30 years of age than in those
over 60.

In view of these variations,

it has been suggested that

the fetal gene for AFP production may undergo reactivation in the
adult more readily under the influence of certain genetic or
etiological factors and at younger ages. ^

Abelev^4 has suggested

that the findings of elevated AFP levels in apparently healthy
adults from "high risk" regions (Senegal and Congo)105,106 may be
the evidence of an enlarged initial pool of the "precursor cells"
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(oval cells whose conversion into small hepatocytes during liver
regeneration in the presence of carcinogens has been correlated with
maximal AFP production)0r of an easiness of their activation*,
This, he believes, might be a basic reason for the comparatively
high frequency of primary hepatocellular carcinoma among certain
human populations.
Partial hepatectomy in humans has been reportedly associated
with AFP synthesis,but such reports have been episodical
and often contradictory.This has tended to support the
conclusion that human AFP cannot be simply a product of regenerating
hepatocytes.

68

Abelev

104

has chosen to differentiate between the

type of hepatic regeneration seen after hepatectomy and that
observed during the acute phase of chemical carcinogenesis.
Watabe^’ has demonstrated that AFP synthesis during the acute
phase of chemical carcinogenesis in the liver takes the form of
a steep wave which drops off until the actual appearance of
hepatoma, but rises sharply again with tumor development.

Abelev

explains that the basic process of regeneration after hepatectomy
involves proliferation of pre-existing hepatocytes as shown by
Leduc.

112

During the poisoning of liver cells by a carcinogen and

liver regeneration in its presence, however, new hepatocyte
formation takes place from the precursor cells with complete renewal
of the hepatocyte population.

This basic difference,

suggests

Abelev, may well be the explanation for inconsistent findings of
AFP synthesis after hepatectomy as compared to the well documented
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AFP rise which accompanies chemical carcinogenesis.
Abelev^*^ believes that his "precursor cells" are at
greatest risk for undergoing tumor transformation and as such
represent target cells for such transformation.

He suggests that

the initial action of a carcinogen is to be selectively toxic for
mature differentiated hepatocytes and cause their degeneration.

This

results in proliferation of "precursor cells" as part of the
regeneration process, and simultaneously increases the target
cell population for tumor transformation.

The actual transformation

may be due to the action of an activated virus, a chemical
carcinogen, or may be spontaneous, but a critical number of target
"precursor cells"

is certain to have been created by the action of

the initial carcinogen.
After surgical resection of the tumor mass in cases of
hepatoma, elevated serum AFP levels have been observed to decrease
temporarily,decrease to a steady level.or eventually
disappear.
level,

78

In cases of a decreased, but steadily maintained

it has been suggested that this pattern may be due to

incomplete removal of the tumor mass with viable cells continuing
to elaborate AFP, but with a lower total production.

Complete

disappearance of AFP may indicate rejection of remaining tumor
cells by a host cellular immune response, but is not generally
70

regarded as confident evidence of cure. 0

Reappearance of AFP or

an increase in levels is generally regarded as evidence of recurrence
of disease.

Therapeutic regimens other than surgical resection
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(i,e,, chemotherapy, radiotherapy) have generally been regarded
as having little if any effect on altering AFP levels,
There is no evidence that benign liver tumors (hamartomas,
adenomas, hemangiomas) or bile duct carcinomas are associated with
elevated serum AFP levels.

Hepatic metastases from cancer of the

stomach and from pancreatic adenocarcinomas have, however, been
reported to have had accompanying elevations in serum AFP,J'^)
With regard to the concept of de-differentiation and reversion
to fetal growth patterns mentioned earlier, numerous authors
have attempted to determine whether the AFP seen in the case of
primary hepatocellular carcinoma is the same as that normally
elaborated by the fetal liver.

On the basis of analyses of

*73
6V
physical and chemical properties, ° and immunologic properties.
4
118,117,74

it has generally been concluded that both normal fetal

and cancerous liver cells produce alpha-fetoproteins which are
structurally indistinguishable and probably identical.
In addition to hepatocellular carcinoma, elevated AFP levels
have also been demonstrated to be consistently associated with
teratocarcinomas of the testis and ovary.

This observation was

independently and simultaneously made for the first time by
Masopust et ai,

ftf)

77

and Abelev'

in 1968.

Both experimenters found

the protein to be present by gel precipitation in approximately
50% of untreated patients with highly undifferentiated tumors.
Proceeding from the original observations cf Gitlin and Boesman-^8
that the endoderm of the fetal yolk sac was capable of AFP synthesis.
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as well as from the fact that structural analogues of the yolk
sac are characteristic of teratoblastomas*Abelev^ suggested
the elaboration of AFP by these tumors might be due to the presence
in them of functioning yolk sac,

Gitlin et al,

also suggested

that analogues of the endoderm of fetal yolk sac and primary gut
present in teratocarcinomas could determine AFP production by them,
1 o *i

Work by Mawas et al,

*1 <^9

1 and Engelhardt et al,"^ has provided direct

confirmation of this hypothesis.
Estimation of AFP levels in patients with teratoblastorna
has essentially the same diagnostic and prognostic value as in the
case of hepatoma.

Detection of AFP by gel diffusion in the

appropriate clinical setting can be considered virtually diagnostic
of teratoblastorna or hepatic carcinoma,

AFP levels can decrease to

normal after surgical intervention as in the case of liver tumors*
and reappearance of elevated levels carries the same ominous prognosis.
Similar to the findings in the case of hepatic tumors.* Mawas
et al.123 ^reported a relationship between age of the patient and
the appearance of elevated AFP levels.

High levels were found in

56% of patients less than 15 years of age* but in only 15% of older
patients.

No elevation of AFP levels have been demonstrated in

other childhood tumors such as neuroblastoma* nephroblastoma*
osteosarcoma* embryonal carcinoma* various brain tumors* liver
angioma, and lymphoreticulosarcoma.123
The presence of elevated AFP levels in certain non-neoplastic
liver diseases was first demonstrated by Alpert et al„y

who
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reported such elevations in patients with viral hepatitis.
Since that time, transient elevations in AFP levels have been
reported by others in cases of viral hepatitis*
alcoholic cirrhosis.

197

*

194.196

s"

Abelev

qq

1ps

'*

I 04

and

has shown that AFP levels

rose between 15 and 30 days after the onset of viral hepatitis and
returned to normal between 15 and 26 weeks thereafter,

Chandra'*'00

reported a higher percentage of AFP-positive sera in young hepatitis
patients than in adult patients,

Karvointzis and Redeker

u note

that the highest AFP levels are found in the most severe cases and
that the appearance of AFP in the sera of patients in coma is
followed by recovery.

This may be due to the association of AFP

synthesis with hepatic regeneration.
The association between elevated AFP levels and chronic
liver disease was also reported by Belanger et al*

190
'

These

experimenters detected elevated AFP in the sera of eight patients
with hereditary tyrosinemia.

This inborn error of metabolism is

associated with Fanconi's Syndrome* and in addition is marked by
progressive degeneration and cirrhosis of the liver.

It is

characterized by an autosomal recessive pattern of inheritance.
In cases of very early onset* hepatic symptoms predominate* and
death from hepatic insufficiency may result during the early months
of life.

The development of malignant hepatoma may occur in those

patients who survive long enough, and this may have some bearing
on the presence of elevated AFP levels.
As was mentioned earlier in this paper (See "Introduction," p. 1)
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Chandra et al.

3

suggested in March 1975 that a strong correlation

existed between elevated serum AFP levels and the presence of the
CF Gene,

Employing techniques of gel diffusion, counterimmunoelectro-

phoresis, and radioimmunoassay, they measured the levels of AFP in the
sera of 22 healthy controls, 18 children with CF, 16 parents of
children with CF, 14 siblings of CF children, 7 patients with
celiac disease, and 7 patients with bronchiactasis.

AFP levels

were found to be elevated in all CF patients (Range ~ 56-8825^g/l|
Log mean = 690 - 1,18), 15 parents (Range = 25-568/<g/l; Log
mean = 178 - 0,85), and 7 siblings (Range for all sibs = 6-400/^g/lj
Log mean = 43 - 1,60; Range for elevated sibs = 75-400/^g/l),
All others fell in the normal range of 5-25Ag/l,

There was no

overlap observed between the AFP levels in normal controls and
in obligate heterozygotes (parents).

No correlation between AFP

level and severity of symptoms was found.

The experimenters

interpreted the bimodal distribution of values among siblings
tested as reflecting those heterozygous for the gene (elevated
values) and those who were not carriers.

They suggest, on the basis

of their results, that AFP be considered a marker for the CF Gene, and
that serum AFP concentrations should be determined in all firstdegree relatives of patients with CF in order to identify the
carrier state.

Acknowledging that the pathogenesis of liver

involvement in CF is unclear, they suggest that the CF Gene
may adversely affect normal processes of maturation in the
fetus (especially in gut-associated tissues such as the liver)
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resulting in the persistence of cell lines capable of synthesizing
AFP and simultaneously making the liver more susceptible to damage
such as fibrosis* cholestasis3 and multilobular cirrhosis.
Since the time that the current study was begun* other
investigators have considered the findings of Chandra's group in
their own radioimmunoassay studies.

Three British investigators

s

131,132 were unable to support the findings while an American expertmenter

reportedly did*

Wailwork et al. ° ; examined 37 CF children*

24 of their parents* and 10 of their siblings and found AFP
concentrations in all to be well within their normal limits
1 n1

(25 ng/rnl) with a median value of 10 ng/ml.

Brock et al.

reported a similar normal range (3,4-18.0 ng/ml) and found that
the seven CF patients tested fell well within it (2.0-9.25 ng/ml).
Fitzsimmons et al.^2 examined 46 CF patients* 31 siblings, 80
obligate heterozygotes (parents)* and 23 normal controls.

This

group’s findings are interesting in that they found a wider range
of AFP values among controls (3-51 ng/ml; median = 9)* but they too
found no difference between these values and those of the CF
heterozygote and sibling groups (CF range = 1-44$ median = 11;
Heterozygote range ~ 1-41; Median ~ 9; Sibling range = 1-55; median = 9).
Smith’s'

data* however, does support that of Chandra et al.

He

examined the sera of seven children with CF and found the mean AFP
value to be 1825 ng/ml with a range of 130-2360 ng/ml.

Fourteen

parents had a mean of 433 (range = 80-1055) ng/ml and three out of
eleven siblings showed AFP elevations (840, 1365, and 1980 ng/ml
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The range for normals was not provided.

These contradictory findings suggested the possibility that
AFP levels might indeed be used as a marker for the CF Gene and
confirmed the need for further work to resolve this important question.

MATERIALS AND METHODS

Subjects

Members of the homozygote group were all outpatients of the
YNHH CF Clinic who were having blood drawn for other tests®

There

were twenty-two subjects in this groups of whom fifteen were male
and seven were female.

Ages in this group ranged from 6 years

to 24 years with a mean age of 13.6 years.

Because of the

] 34
negative results of this study, Swachman scores '
which were to
have been used to correlate CF severity with AFP levels were not
determined.

None of the subjects were malnourished or cyanotic,

and all had normal liver function tests at the time that the
specimens were obtained.

Diagnosis of CF had been established by

pilocarpine iontophoresis with sweat chlorides higher than oOmmol/l.
Members of the heterozygote group included twenty male and
thirty-three female parents of children seen in YNHH CF Clinic.

All

were in good health at the time the specimens were obtained., and
all were without any history of chronic disease.

Ages in this

group ranged from 23 to 56 years with a mean age of 36.7,
There were twenty members of the normal control group.

These

included five male and seven female children seen at the YNHH
pediatric clinic for well child care who were having routine bloods
drawn* two female asymptomatic siblings of CF patients, and six
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male YNHH medical student and house staff volunteers*

Ages in

this group ranged from 2 to 34 years with a mean age of 16.1*
All were in good health with no history of chronic disease.
All subjects in the three groups were Caucasian.

Collection of Specimens

Specimens from Pediatric and CF Clinics were drawn into a
plastic syringe from a clean venopuncture by using a #21 butterfly
needle.

The blood was then immediately placed in a red-topped

glass Vacutainer test tubes refrigerated at 4°C9and allowed to
clot.

Specimens were then spun at 3000 rpm for 15 minutes.

Serum

was removed by Pasteur pipets aliquotted into 2cc bottles., labelleds
and frozen at -20°C»

Care was taken to thaw each specimen only

oncea immediately prior to use.

Isolation of AFP

Purification of AFP was accomplished in essentially the manner
described by Nishi'-3 and employed by Ruoslahti and SepphlS.

Known

rabbit antiserum to AFP (used by the YNHH Clinical Immunology Lab
for AFP quantification) was combined with an AFP source (amniotic
fluid and sera from legally aborted fetuses) after determination
of the appropriate antigen-antibody ratio by a method of immunoprecipitation in capillary tubes.

The antiserum-AFP mixture was
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incubated at 37°C for one hour and then stored for fourteen hours
at 4°C.

The mixture was then spun at 3000rpm for 15 minuteso

The supernatant was removed* saving the precipitate of antigenantibody complexes-

The immuno-precipitate was washed several

times in normal saline and then dissolved in 0*1 M glycine/B31 (pH = 2)
to disassociate the antigen-antibody complexes*

Separation of free

AFP from free antibody and antigen-antibody complexes was then accomplished
by gel filtration on Sepnadex G-200.

Glycine/HCl (0.05M) in normal

saline (pH - 2) was used for elution and the collected fractions
were brought to neutral pH (pH = 7,4) with appropriate amounts of
0.2M Phosphate Buffer*
This process was repeated several times as antisera more
specific in their binding of AFP became available* resulting in
purer isolates of AFP,

In order to remove all possible contamination

of AFP by components of normal human serum* a pellet was made by
polymerizing rabbit anti-whole human serum with glutaraldehyde.
The pellet was incubated with the AFP containing eluates for one
hour at 37°C and then refrigerated at 4°C for 20 hours.

The samples

were then centrifuged at 3000rpm for 15 minutes and the AFPcontaining supernatant was removed.
techniques

Immunodiffusion by the Ouchterlony

showed lack of immunoprecipitation of purified AFP

by rabbit anti-whole human serum* but a strong single line of
precipitation by raboit anti-AFP indicating the purity of the
preparation (Figure I),

Immunoelectrophoresis also revealed

a single line of precipitation.
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Fl'GURE I
Purity of Isolated AFP

Figure I.

Large well contains purified AFP.
Small well contains
specific anti AFP serum.
Single line of irnmunoprecipitate
indicates purity of preparations.

The AFP eluates obtained in this manner was quantitated by
standard immunodiffusion techniques employed at the YNHH Clinical
Immunology Lab and was found to contain approximately 35 micrograms
AFP per milliliter.
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Production of Antiserum

Anti-AFP serum used in this study was produced in four
laboratory rabbits over a

two

month period of time.

The initial

sensitization was accomplished by injection of 1 ml of a suspension
of purified AFP in Complete Freunds Adjuvant into the foot pads
and dorsal fat pads of the four rabbits.

The injections were

repeated twice more at four week intervals with 1 ml of a
suspension of purified AFP in Incomplete Freunds Adjuvant,

The

rabbits were bled 10 ml on four separate occasions by intracardiac
puncture at approximately three week intervals after the initial
sensitization.

After each bleeding, the sera obtained were

tested for immuncprecipitation of normal human serum and of AFP.
The antisera continued to produce specific immunoprecipitation of
AFP (Figure II) with no precipitation of normal human serum
components, and were utilized in the isolation of additional AFP
for injection into the rabbits.
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FIGURE II
Specificity of Rabbit Anti-AFP Sera

Figure II.

Large center well contains purified AFP.
Small wells
contain one of four different AFP-specific antisera.

Counterimmunoelectrophoresis

All specimens were tested for the presence of detectable
AFP by a well established technique of counterimmunoelectrophoresis
(CEP) routinely used in the YNHH Clinical Immunology Lab.

The
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technique involves use of a 3 X 4 inch glass plate coated with 2%
Agarose in Barbital Buffer (pH 7.4).

Serum with a previously

determined quantity of AFP (66 piq/ml) was diluted to an AFP
concentration of 300 nanograms per milliliter and was included on
each CEP plate.

This control was readily detectable as being

positive for AFP, thus establishing a sensitivity for the technique
of at least 300 nanograms per milliliter.

Current re-evaluation of

the CEP technique suggests that its sensitivity may actually be
in the region of 150 nanograms per milliliter.

This re-evaluation,

however, is as yet incomplete and so, for the current study, the
300 nanogram figure was employed as the lower limit of sensitivity
for the CEP.

Radioiodination of AFP

Iodination of purified AFP was accomplished by a modification
of the technique described by Greenwood and Hunter.137

Twenty

microliters of 0.2 M phosphate buffer (pH = 7.4) was added to
200 microliters (7 micrograms) of AFP.

To this was added 10 microliters

of 5 nCi/ml Na^^l in dilute NaOH solution, pH 8-11 (The Radio¬
chemical Centre, Amersham, England).

Five microiiters of 0.05 M

phosphate buffered saline (PBS), pH 7.4 containing 25 micrograms of
chloramine-T was immediately added.

After approximately 10

seconds* mixing, lO microiiters of PBS containing 150 micrograms of
sodium metabisuiphite, followed by 20 microiiters of PBS containing
332 micrograms of potassium iodide, were added.

Incorporation of
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125
^1 into AFP was determined by gel filtration on P-30 polyacrylamide
gel

(1 X 20 cm column)* which was used to separate the labeled

protein from excess radioiodine.

The labeled AFP was collected

in six-drop fractions into plastic scintillation tubes (Falcon
16 X 25 mm tubes) containing 0«1 ml of 0.05 M PBS.

The degree of

radioactivity in the peak AFP-containing fraction was determined by
a Nuclear-Chicago automatic gamma sample counter.
In order to remove any rabbit protein (remaining from the
AFP isolation process) which might have been randomly iodinated
along with the AFP, the iodinated protein was treated with a
pellet of glutaraldehyde-polymerized donkey anti-rabbit serum in
the manner described for anti-normal human serum in the section
on "Isolation of AFP*"

After removal of the pellet., measurable

radioactivity in the labeled protein sample was found to have
decreased by approximately 30%,

indicating a specific removal of

■*-2^I-labeled rabbit protein, and/or a non-specific absorption of
protein which may have been damaged in the course of iodination.
The immunoreactivity of the labeled AFP was then determined.
In order to do this, the percentage of radioactive AFP precipitated
by a l/2000 dilution of the anti-serum used in the final radio¬
immunoassay was compared with the precentage precipitated by the
same dilution of normal rabbit serum (non-immune).

To 20

microliters of protein carrier (1% Bovine serum albumin in PBS,
pH 7.4) were added 20 microliters of -*-^5l-laheled AFP (diluted
with 1% BSA so as to contain 10,000 counts per minute), and 20
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microliters of either 1/2000 rabbit anti~AFP serum or l/2000
normal rabbit serum.

After adequate mixing, this was allowed to

stand at 4°C for 20 hours.

At this time, the samples were spun

in a Sorvall RC2-B refrigerated centrifuge for 20 minutes at
15000 xpm and 5°C.

The supernatant and precipitate, were then

separated, with each being placed in a separate Falcon
scintillation tube.

The radioactivity present in each tube was

then counted for one minute by a Nuclear-Chicago automatic gamma
sample counter.

The percentage of the total radioactivity for

each sample which was present in the immunoprecipitate was then
calculated.

The presence of 95% or more of the total radioactivity

in the supernatant of the normal rabbit serum samples was considered
acceptable, with the remaining 5% or less remaining in the original
reaction vial due to nonspecific effects.

Immunoprecipitation of

25% or more of the labeled AFP by the immune serum was considered
as evidence that the radioactive protein was sufficiently
immunoreactive for use in radioimmunoassay.

'I-labeled AFP

showing less than 25% binding was considered adequate for use in
immunoautoradiography.

Immunoautoradiography

Eighty-four (all CF sera and a random selection of 14 normals
and 48 heterozygotes) of the ninety-five specimens collected for
this study were tested for the presence of detectable AFP by a

39

-

-

technique of immunoautoradiography.

A similar technique employed

by Abelev et al.^8 was able to detect AFP in the sera of pregnant
women and patients with hepatitis.

Six standard dilutions of AFP

positive fetal serum (previously quantitated in triplicate at
50 micrograms per milliliter) were made so as to contain 150, 100,
70, 50, 30, and 20 nanograms of AFP per milliliter.

These dilutions

were made by adding appropriate amounts of AFP-negative (by
Counterimmunoelectrophoresis) normal human serum and enough

1 pq

I-labeled AFP to provide 20,000 cpm in 25 microliters of the

final mixture.

In order to remove any possible traces of AFP,

the normal human serum used for dilution had previously been
incubated with a pellet of glutaraldehyde-polymerized specific
anti-AFP serum in a manner identical to that described for the
purification of AFP with a pellet of polymerized anti-whole human serum
(see "Isolation of AFP," p. 31).

It was determined by use of a

normal rabbit serum control that such a pellet was able to
absorb on the order of 100 nanograms of AFP (or 50 nanograms per
milliliter for the 2.0 milliliter samples of normal human
serum processed for dilution), which should well represent virtually
all of the AFP present in a sample of normal human serum (Ruoslahti
and Sepp^l^'had found levels of AFP from

1.5-16 nanograms

per milliliter in specimens of normal human serum).

This determination

was made by adding a known amount of AFP (from a fetal serum source)
to whole normal rabbit serum, incubating this sample with a pellet
of polymerized anti-AFP serum, and then quantitating by

radioimmunoassay techniques the amount of decrease in AFP.
Also prepared were an AFP-positive control quantitated at
94 nanograms AFP per milliliter and a negative control containing
only the normal human serum used for dilution with no unlabeled
AFP added.
added enough

To these controls and to each of the sera tested was
labeled AFP to provide 20,000 cpm in 25 microliters.

The AFP dilutions (to provide a standard curve for quantification
of unknown samples), the two controls., and thirteen unknown samples
were set up in duplicate on each immunoautoradiography plate.
The plates consisted of 3 X 4 inch glass slides coated with 15.0
milliliters of Special Noble Agar prepared in normal saline and
containing 4,0 microliters of anti-AFP serum per milliliter (for
immunoprecipitation of any AFP present).

Forty-two wells, each

holding 25 microliters of sample, had been cut into the agar.

The

plates were allowed to stand in moist plastic chambers at room
temperature for 43 hours.

They were then immersed in normal

saline and allowed to wash at room temperature for another 48 hours.
At that time they were removed from the saline and wrapped in a
single layer of Saran Wrap.

In a darkroom, 3X4 inch pieces of

Kodak P.P-14 Medical X-ray film were placed in contact with the
agar coated side of each plate, and they were appropriately
stored so as to avoid exposure to light.

After one week, the

exposed sheets of film were developed using Kodak Dental X-ray
Developer, and then contact printed onto Agfa (Grade 6) High Contrast
photographic paper.

The diameter of the circle of exposure for
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each well was measured with an average of the diameters
duplicate wells being taken.

of

Values to provide standard curves

from which the values of unknown specimens could be estimated.

Radioimmunoassay (RIA)

The technique employed for RIA was a non-equilibrium one
in which addition of ^^I-labeled AFP was made after the test
samples had been incubated with the anti-AFP antiserum for
48 hours.

The double antibody technique employed by Ruoslahti

and Sepp&lS^^ and by Purves and Purves^^ was considered.

This

technique* however (attempted with goat anti-rabbit serum)*
showed no advantage in the ability to precipitate anti-AFP
serum bound

I-labeled AFP over (NH^)^0/j in our hands.

We

therefore elected to use the ammonium sulfate as it was more
readily available.
in PBS

Twenty microliters of a 1% solution of BSA

(pH 7.4) were included in each sample as a protein carrier.

Early experiments had exhibited a problem with adherence of
labeled AFP to the sides of the reaction vessel.

This was

eliminated by inclusion of the BSA.
In preparation for the radioimmunoassayfl the appropriate
dilution of antiserum for use was determined.

Anti-AFP serum

dilutions of l/lOOO* 1/2000*

1/3000* l/4000s and l/8000 were

prepared with PBS

Twenty microliters of each dilution

(pH 7.4).

were added in duplicate tubes (Fischer polyethylene centrifuge
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1 ml capacity) containing 20 microliters of a 1% solution

of BSA in PBS

(pH 7.4).

To this was added 20 microliters of

I-labeled AFP diluted with 1% BSA so as to give 3000 counts per
minute.

The tubes were mixed with a Vortex mixer and then

incubated at 37°C for one hour.

They were then refrigerated at

4°C for 20 hours* after which time 0.2 milliliters of a 43.5%
solution of ammonium sulfate were added.
were again stored at 4°C for 20 hours.
at 15000 rpms

After mixing* the tubes
They were then spun

5°C in a Sorvall RC2-B automatic refrigerated

centrifuge for 20 minutes.

The supernatant was removed by

Pasteur pipet and the radioactivity in both supernatant and
precipitate were counted.

The results are plotted in Figure III.
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FIGURE III
Antiserum Dilutions

in
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Antiserum Dilution (XlCT^)

The antibody concentration binding at least 25% of the precipitable
counts*

in this case 1/2000* was selected for use in the assay.

In order to obtain a standard inhibition curve from which to
determine the level of AFP in unknown samples, standard dilutions
of AFP-positive fetal

serum (previously quantitated in triplicate)

were made using the absorbed normal human serum described earlier as
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diluent (See ".Immunoautoradiography8" p. 38).

Seven such dilutions

were made so as to contain 15* 259 50, 75, 100, 150, and 200
nanograms of AFP per milliliter, respectively.

Three standard

curves were set up in duplicate, one with each of the three
batches of unknown sera which wrere run.

In each 1 ml centrifuge

tube, 20 microliters of AFP dilution and 20 microliters of a
1/2000 dilution of anti-AFP serum in 1% ESA were added to 20
microliters of 1% BSA in PBS

(pH 7.4).

This was thoroughly

mixed, incubated for one hour at 37°C and then stored for 48 hours
at 4°C.

At this time 20 microliters of ^^I-labeled AFP diluted

in 1% BSA so as to contain 3000 counts per minute were added*

The

samples were again mixed, incubated at 37°C for one hour, and
stored at 4°C for 24 hours,
solution of ammonium sulfate

A 0*2 milliliter quantity of a 47.5%
PBS

(pH 7,4) was then added.

samples were mixed and stored at 4°C for 24 hours.

They were then

spun in the Sorvall P.C2-B for 20 minutes at 15000 rpm,
supernatant was removed by Pasteur pipet.

The

5°C«

The

Supernatant and immuno-

precipitate were placed in separate Falcon 16 X 25 mm tubes for
counting on a Huclear-Chicago automatic gamma counter.

The results

were plotted on Semi-Log graph paper (#cpin in precipitate///cpm in
supernatant or BOUNd/fPyEE

v_s

Concentration of AFP in ng./ml).

Each series included two control tubes in duplicate.

One control

contained the same processed normal human serum used for dilution,
but had no added "cold" AFP ("Trace Tube").

The second control

also contained normal human serum without added AFP, but the anti-AFP
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serum was also omitted from this tube.

The counts observed in the

precipitate of this tube represent non-specific radioactivity, or
the Percent of Damage for the assay.

This Percent of Damage was

subtracted from the precipitated counts for both the standard curve
and unknown samples prior to calculating the “/? ratio and plotting
these values.
represent

The ®/f values appearing in the graphs therefore

the corrected ®/F ratios.

The undiluted sera of CF patients, heterozygotes, and normals
were tested in duplicate using 20 microliter samples as in the case
of the AFP dilutions.

The setting up and processing of these

specimens was identical to those for the standard inhibition curve
save for the substitution of the unknown samples in place of the
AFP dilutions.

All samples were thawed for the first time

immediately before use in the assay.

I

RESULTS

Counterimmunoelectrophoresis

None of the ninety-five sera tested in this study showed
any visible evidence of immunoprecipitation with anti-AFP serum
on counterimmunoelectrophoresis.

The positive control (containing

300 nanograms AFP per milliliter)

included on each plate was

clearly distinguishable as positive for AFP* a single line of
immunoprecipitation being easily visible.

Immunoautoradiography

)
The standard curve used to estimate the values of AFP concentration
in unknown samples and to establish the lower limits of sensitivity
of the technique is presented in Figure IV.

It was found that the

sensitivity of immunoautoradiography technique was approximately
70 ng/ml in our hands.

AFP concentrations above this value were

readily distinguishable from each otherj while those below
70 ng/ml produced rings of exposure of virtually identical diameter.
Ring diameters for all standard curve dilutions and all unknown
sera were measured to the nearest 0.5 mm.

It was found that none of

the 84 sera tested by this technique produced a ring diameter which
would indicate an AFP concentration greater than 70 ng/ml. A sample
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of the contact prints from which the determinations were made 5s
presented in Figure V.

This particular plate contains 13 CF sera

in duplicate in the lower four rows.

Included on each plate was

an AFP-positive controls previously quantitated at 9A ng/ml by
gel immunodiffusion techniques.

The observed ring diameter for

these samples was measured at 11 mms which, when squared and
plotted on the standard curve, showed a value of 95 ng/ml, indicating
the accuracy of the immunoautoradiography technique.
FIGURE V.

Immunoautoradiography Samples
COLUMNS

Figure V.

All samples are presented in duplicate.
Measurements
made were of the horizontal diameter of each ring.
ROW 1 & 2:
AFP dilutions of 150, 100, 70, 50, 30,
and 20 ng/ral in COLUMNS 1-7. COLUMN 7 contains AFPpositive control (9d ng/ml). ROW 3 & A:
COLUMN 1
contains AFP-negative normal human serum. COLUMNS 2-7
contain CF sera. ROWS 5 & 6:
COLUMNS 1-7 contain
CF sera.
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Radioimmunoassay

1.

Standard Inhibition Curve

The standard inhibition curves from three separate trials
are presented in Figure VI* plotted on a semi-logarithmic scale.
The relationship between the concentration of AFPS and the
inhibition obtained is linear from 25-100 ng/ml,

This* then*

represents the lower limit of sensitivity (25 ng/ml)* and the
working range (25-100 ng/ml) of the assay.

Values for AFP

concentrations less than 25 ng/ml and greater than 100 ng/ml
cannot be assigned.

2.

Serum Samples

The results of AFP concentration measurements in the unknown
sera are depicted in Table II.

Log means are presented in addition

to the arithmetic means so that the results can be compared directly
to those of Chandra et al«^

Of the 22 CF sera tested* 17 had

AFP values in the < 25 ng/ml range; 8 had values in the measurable
range (Range = 26-32; X = 28.4);

none had values >100 ng/ml.

Thirty-two of 53 parents had AFP values of <25 ng/rnl; 20 had
measurable values (Range = 25-53; 5< = 28.8); and one had a value
>100 ng/ml.
range.

Both siblings tested had AFP values in the <25 ng/ml

Of the 18 healthy controls* 10 had AFP values of <25 ng/ml;

50-

-

Log AFP (ng/mi)

FIGURE VI
Radioimmunoassay Standard Curve
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8 had values between 25 and 100 ng/rnl (Range = 25-28; 2 = 26.6);
and none had values >100 ng/ml.

The heterozygote serum which

was measured at >100 ng/rnl was re-evaluated by counterimmunoeiectrophoresis and OuchterlBny gel diffusion and again proved negatives
suggesting that if this is a true elevations the actual value should
fall between 100 and 300 ng/ml.
Statistical analysis (Fisher's "Exact Test") evaluating all
possible group pairs failed to demonstrate any statistically
significant differences (p > .10 for all pairs).

TABLE II
Radioimmunoassay Results

NUMBER
& SEX

<25 ng/ml
NO.

No.

25-100 nq/ml
X
L.M.
MED.

RANGE

>100 ng/ml
NO I

M 15
PATIENTS 22 F
7

17

5

23.4

28.3
±1.1

28

26-32

0

M li
CONTROLS 18 F
7

10

8

26.6

26.6
±1.0

26.5

25-28

0

0
2

2

0

—

-----

0

M 20
53 F 33

32

20

28.8

25-53

1

SIBLINGS

PARENTS

M
2 F

23.3
±1.1

27.6

X = Arithmetic Mean; L.M. = Log Mean - Standard Error of Mean;
MED. = Median.

DISCUSSION

The original report by Chandra et al.^ of an elevated level
of AFP in children with CF seemed based on a reasonable premise.
The involvement of the liver in CF has been well documented with
localized foci of biliary obstruction and fibrosis commonly found
at autopsy., even in infants.

In some patients, particularly

those in their teens, these changes progress and cause a distinctive
type of multilobular biliary cirrhosis with large irregular nodules.
The relationship between non-malignant liver disease and elevated
1 OO

AFP levels has been documented,

1 OS

* '

and it therefore seemed

entirely possible that AFP levels might well be elevated in CF
patients with their chronic liver involvement.

The CF Gene could

well affect normal maturation processes so as to result in the
persistence of embryonic cell lines capable of AFP synthesis,
and to make the liver more susceptible to damage as Chandra lias
suggested.

3

The current study has, however, by three separate

systems of measurement characterized by differing levels of
sensitivity, failed to support the results of Chandra and his
co-workers.

Counterimmunoelectrophoresis, easily able to

demonstrate the presence of AFP concentrations as low as

300 ng/ml

(and possibly as low as 150 ng/ml), failed to detect the presence
of AFP in any of the samples tested.

This already placed the

level of AFP concentrations in Cf and heterozygote sera well below

52-

-

53-

-

those reported by Chandra et al.s and indicated that they were
certainly lower than 300 ng/ml,

Though clearly lower than the

levels reported, the possibility still existed that CF and heterozygote
serum AFP concentrations might still fall in an elevated range.
This range of possible elevation was further decreased by use of
immunoautoradiography.
technique

The lower limit of sensitivity of this

having been established at

70 ng/ml by use of a

standard curve, it was found that none of the samples tested fell in
the range above 70 ng/ml.

An AFP-positive control (previously

quantitated at 94 ng/ml) was included on each of the autoradiography
plates.

Plotting the square of the diameter measured for this

sample (diameter ^ = 121) yielded a value of 95 ng/ml from the
standard curve, indicating the acceptable accuracy of the technique.
Radioimmunoassay with a sensitivity limit of 25 ng/ml
established that all but two samples tested fell in the normal
range.

The sample whose AFP concentration fell in the greater than

100 ng/ml range was retested by counterimmunoelectrophoresis, and
was again negative.

This suggests that if the radioimmunoassay

estimation is correct, the subject's serum AFP concentration lies
somewhere between 100 and 300 ng/ml.

The subject, an obligate

heterozygote, continues to enjoy good health with no evidence of
chronic disease.

Due to a limited supply of radio-labeled AFP, this

subject's serum was unfortunately one of eleven sera which were
randomly eliminated from the group evaluated by immunoautoradiography.
We are therefore unable to confirm the observation of an elevated
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AFP concentration by this technique.
The second elevated serum was quantitated at 53 ng/ml.
This value is quite similar to that of 50 ng/ml described by
Ruoslahti

and Sepp&lh^' in a normal (non-carrier of CF) healthy

24 year old male with no detectable liver disease or history of
any other chronic disease.

The subject in this study3 though

a heterozygote, is equally healthy.

Occasional elevated values

in clinically healthy subjects carry an unknown significance
at this time.

While they may well bespeak the presence of some

underlying defect or subclinical disease entity, they must be
regarded as normal variants until such a relationship can be
demonstrated.
The range of AFP concentrations observed among normals in
this study ( 25 to 28 ng/ml)

exhibits a slightly higher upper

limit than that of some experimenters^1^ (up to 25 ng/ml), but
is well within the range observed by others^^ (3-51 ng/ml).

It

seems clear that there is considerable room for normal variation
in the AFP concentrations measured by sensitive techniques such as
radioimmunoassay.

The mean and median values for the samples

which could be accurately quantitated in our study are both higher
than those observed in other studies measuring AFP by the same
means.

The reason for this is that the sensitivity limits of our

assay were such that we were unable to accurately quantitate
those values which fell in the less than 25 ng/ml range.

Thus, our

mean and median values represent only those AFP concentrations which
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fell in the 25-100 ng/ml range.

It is expected, from the number of

values which fell below 25 ng/ml, that accurate quantification of
these lower values would have resulted in mean and median values
more closely resembling those of other experimenters.
Vie were somewhat disappointed with the narrow working range
(25-100 ng/ml) of sensitivity of our assay.

Though we were able

to compensate for limitations on the upper end of the range by
use of the counterimmunoelectrophoresis and immunoautoradiographic
techniques,

it would have been desirable to have had a lower limit

of sensitivity in the region of 1-2 ng/ml, though Ruoslahti and
SeppSlH

have reported a sensitivity threshold of 250 picograms/ml,^J

The limiting factor appears to have been the inability to achieve
high enough antibody titers in the two month period of time over
which the rabbits were immunized.

The specificity of the antibody,

despite its low titer, appeared to be high as evidenced by specific
immunoprecipitation seen on gel immunodiffusion and Immunoelectro¬
phoresis.

Evidence of the relatively low antibody titer is provided

in Figure III which demonstrates that specific binding by our
antibody falls off considerably in going from a l/2000 to a 1/3000
dilution.

Binding is almost non-existent at a l/SOOO dilution,

Ruoslahti and SeppcllS-LO'J in contrast, report near maximal binding
at an antiserum dilution of 1/25000, with significant binding still
occurring with the antiserum diluted 1/3,000,000.
with a sheep antiserum produced by 5 months'

This was achieved

immunization.

Because

of the low antibody titer, we were also' unable to employ dilutions

-t>6-

of our test sera since this would have placed our Working range in
the region of the sensitivity of the autoradiography technique.
Despite these problems, however, our sensitivity threshold is
almost the same as the 20 ng/ml level achieved by Purves and Purves^
who also used undiluted test sera, though their working range was
broader (20**1000 ng/ml).
Perhaps our greatest disappointment was in the fact that we
were unable to provide evidence in support of the usefulness of
serum AFP levels as a marker for the CF heterozygote state.
We were somewhat concerned when, after having begun our study,
we noted the negative results reported by the three British
investigators,

but. remained hopeful that we migru. see

positive results in this study until the time that our own data
became final.
The reason for the contradictory findings is unclear.

In

view of the fact that the published data suggesting the
correlation between AFP and CF has come from sources on this side
of the Atlantic while those denying it come from

Europe, it is

conceivable that there is a basic difference between CF in the
two settings.

We know of no such differences, and our data would

seem to tip the scales against such a hypothesis.

Differences

in therapeutic regimes seem unlikely as the cause for elevated
AFP levels as elevations were reported in heterozygotes who
presumably receive no such treatment.
It is conceivable that Chandra’s assay was measuring the
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presence of some factor other than AFP,

Confirmation that AFP

was indeed the factor whose levels were measured could be made by
use of immunoabsorbents in the manner described by Ruoslahti and
135
Sepp’llS,' '

These experimenters absorbed AFP from test samples

containing measurable amounts (by radioimmunoassay) of AFP by means
of a glutaraldehydepolymerized specific anti-AFP serum in the manner
described earlier in this paper.

The test sera (with AFP removed)

were re-tested by radioimmunoassay for the presence of AFP,

Absorbed

AFP was freed from the glutaraldehyde pellet by acid dissociation
and these samples were then re-tested for AFP content.

While the

same process could have been employed in our study, the antiserum
initially used by us for AFP isolation has been reliably used in the
past for AFP detection and quantification, making it quite unlikely
that we might have isolated a serum factor other than AFP.

In

addition, it would seem at this time that the burden of proof is
upon Chandra and his group.

Should Chandra’s antiserum prove

to be binding some factor other than AFP, this would still be
a highly significant finding as any measurable difference able
to reliably differentiate CF patients and heterozygotes from normals
would be a- noteworthy achievement.
In conclusion, our results lend support to those of other
investigators who have failed to find evidence that the measurement
of serum AFP concentrations might be used to identify asymptomatic
carriers of the Cystic Fibrosis Gene.

The need for a reliable method

for heterozygote detection in this disease is a critical one in view
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of its notably high incidence.

-

Without such a method* efforts

to lower the incidence of cystic fibrosis by genetic counseling
will remain virtually impossible.
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